Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
4.1. Effectiveness of Ixekizumab with and Without Induction Therapy
4.2. Long-Term Efficacy and Drug Survival
4.3. Safety Profile of Ixekizumab and Patient’s Reported Outcomes
4.4. Study Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Christophers, E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, 314–320. [Google Scholar] [CrossRef] [PubMed]
- Lebwohl, M. Combining the new biologic agents with our current psoriasis armamentarium. J. Am. Acad. Dermatol. 2003, 49 (Suppl. S2), S118–S124. [Google Scholar] [CrossRef]
- Menter, A.; Griffiths, C. Psoriasis: The Future. Dermatol. Clin. 2015, 33, 161–166. [Google Scholar] [CrossRef]
- Koo, J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. 1996, 14, 485–496. [Google Scholar] [CrossRef]
- Mease, P.J.; Menter, M.A. Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J. Am. Acad. Dermatol. 2006, 54, 685–704. [Google Scholar] [CrossRef] [PubMed]
- Sokoll, K.B.; Helliwell, P.S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J. Rheumatol. 2001, 28, 1842–1846. [Google Scholar]
- Menter, A.; Gottlieb, A.; Feldman, S.R.; Van Voorhees, A.S.; Leonardi, C.L.; Gordon, K.B.; Gottlieb, A.; Koo, J.Y.; Lebwohl, M.; Leonardi, C.L.; et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2008, 58, 826–850. [Google Scholar] [CrossRef] [PubMed]
- Menter, A.; Korman, N.J.; Elmets, C.A.; Feldman, S.R.; Gelfand, J.M.; Gordon, K.B.; Gottlieb, A.; Koo, J.Y.; Lebwohl, M.; Leonardi, C.L.; et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol. 2011, 65, 137–174. [Google Scholar] [CrossRef] [PubMed]
- Mitra, A.; Raychaudhuri, S.K.; Raychaudhuri, S.P. IL-17 and IL-17R: An auspicious therapeutic target for psoriatic disease. Actas Dermosifiliogr. 2014, 105 (Suppl. S1), 21–33. [Google Scholar] [CrossRef]
- Farahnik, B.; Beroukhim, K.; Zhu, T.H.; Abrouk, M.; Nakamura, M.; Singh, R.; Le, K.; Bhuani, T.; Koo, J. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol. Ther. 2016, 6, 25–37. [Google Scholar] [CrossRef]
- Gordon, K.B.; Blauvelt, A.; Papp, K.A.; Langley, R.G.; Luger, T.; Ohtsuki, M.; Reich, K.; Amato, D.; Ball, S.G.; Braun, D.K.; et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N. Engl. J. Med. 2016, 28, 345–356, 375. [Google Scholar] [CrossRef] [PubMed]
- Torres, T.; Chiricozzi, A.; Puig, L.; Lé, A.M.; Marzano, A.V.; Dapavo, P.; Dauden, E.; Carrascosa, J.-M.; Lazaridou, E.; Duarte, G.; et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am. J. Clin. Dermatol. 2024, 25, 333–342. [Google Scholar] [CrossRef] [PubMed]
- Chiricozzi, A.; Megna, M.; Giunta, A.; Carrera, C.G.; Dapavo, P.; Balato, A.; Malagoli, P.; Mazzoccoli, S.; Parodi, A.; Sabatino, S.; et al. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: Results from an Italian retrospective cohort study (the LOTIXE study). J. Dermatol. Treat. 2023, 34, 2246606. [Google Scholar] [CrossRef]
- Burlando, M.; Salvi, I.; Castelli, R.; Herzum, A.; Cozzani, E.; Parodi, A. Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: A single-center experience. Eur. Rev. Med. Pharmacol. Sci. 2023, 27, 4060–4064. [Google Scholar]
- Reich, A.; Reed, C.; Schuster, C.; Robert, C.; Treuer, T.; Lubrano, E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: Literature review 2016–2021. J. Dermatol. Treat. 2023, 34, 2160196. [Google Scholar] [CrossRef]
- Pinter, A.; Puig, L.; Schäkel, K.; Reich, A.; Zaheri, S.; Costanzo, A.; Tsai, T.F.; Smith, S.D.; Lynde, C.; Brnabic, A.; et al. Comparative effectiveness of biologics in clinical practice: Week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J. Eur. Acad. Dermatol. Venereol. 2022, 36, 2087–2100. [Google Scholar] [CrossRef] [PubMed]
- Malagoli, P.; Dapavo, P.; Pavia, G.; Amoruso, F.; Argenziano, G.; Bardazzi, F.; Burlando, M.; Carrera, C.G.; Damiani, G.; Dini, V.; et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis). Dermatol. Ther. 2022, 35, e15608. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Puig, L.; Joshi, A.; Skup, M.; Williams, D.; Li, J.; Betts, K.A.; Augustin, M. Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis. JAMA Dermatol. 2020, 156, 258–269. [Google Scholar] [CrossRef] [PubMed]
- Lockshin, B.; Cronin, A.; Harrison, R.W.; McLean, R.R.; Anatale-Tardiff, L.; Burge, R.; Zhu, B.; Malatestinic, W.N.; Atiya, B.; Murage, M.J.; et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The corrona psoriasis registry. Dermatol. Ther. 2021, 34, e14808. [Google Scholar] [CrossRef] [PubMed]
- Lunder, T.; Zorko, M.S.; Kolar, N.K.; Suhodolcan, A.B.; Marovt, M.; Leskovec, N.K.; Marko, P.B. Drug survival of biological therapy is showing class effect: Updated Results from slovenian national registry of psoriasis. Int. J. Dermatol. 2019, 58, 631–641. [Google Scholar] [CrossRef] [PubMed]
- Sherman, S.; Zloczower, O.; Noyman, Y.; Amitay-Laish, I.; Hodak, E.; Pavlovsky, L. Ixekizumab survival in heavily pretreated patients with psoriasis: A two-year single-Centre retrospective study. Acta Derm. Venereol. 2020, 100, adv00349. [Google Scholar] [CrossRef] [PubMed]
- Gargiulo, L.; Ibba, L.; Malagoli, P.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C.G.; Damiani, G.; Dapavo, P.; Dini, V.; et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses—IL PSO (Italian landscape psoriasis). Front Immunol. 2024, 14, 1341708. [Google Scholar] [CrossRef]
- Avallone, G.; Maronese, C.A.; Murgia, G.; Carrera, C.G.; Mastorino, L.; Roccuzzo, G.; Dapavo, P.; Alberti-Violetti, S.; Quaglino, P.; Ribero, S.; et al. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J. Clin. Med. 2023, 12, 1662. [Google Scholar] [CrossRef]
With Induction | Without Induction | ||||||
---|---|---|---|---|---|---|---|
n | DE | % | n | DE | % | ||
n | 183 | 156 | - | 85.25 | 27 | - | 14.75 |
Gender | Male | 118 | - | 64.48 | 16 | - | 8.74 |
Women | 54 | - | 29.51 | 11 | - | 6.01 | |
Age | 51.83 | 13.33 | - | 54.71 | 13.23 | - | |
BMI (kg/m2) | 28.86 | 6.33 | - | 30.33 | 5.07 | - | |
Baseline PASI | 14.35 | 10.59 | - | 8.95 | 3.96 | - | |
Baseline PGA | 3.40 | 1.10 | - | 2.74 | 0.71 | - | |
Clinical type | Plaque | 149 | - | 95.51 | 27 | - | 100.00 |
Pustular | 4 | - | 2.56 | 0 | - | 0.00 | |
Erythroderma | 10 | - | 6.41 | 2 | - | 7.41 | |
Difficult to treat location | Inverse | 20 | - | 12.82 | 5 | - | 18.52 |
Genital | 29 | - | 18.59 | 4 | - | 14.81 | |
Scalp | 61 | - | 39.10 | 27 | - | 100.00 | |
Nail | 28 | - | 17.95 | 13 | - | 48.15 | |
Palm-plantar | 22 | - | 14.10 | 0 | - | 0.00 | |
Non PsA | 48 | - | 26.23 | 10 | - | 5.46 | |
Peripheral | 44 | 24.04 | 8 | 4.37 | |||
Psoriatic Arthritis (PsA) | Axial | 2 | 1.09 | 0 | 0.00 | ||
Mixed | 2 | 1.09 | 2 | 1.09 | |||
Comorbidities | Diabetes | 21 | - | 11.48 | 3 | - | 1.64 |
Hypertension | 47 | - | 25.68 | 8 | - | 4.37 | |
Dyslipidemia | 25 | - | 13.66 | 6 | - | 3.28 | |
Obesity | 37 | - | 20.22 | 10 | - | 5.46 | |
Metabolic syndrome | 16 | - | 8.74 | 5 | - | 2.73 | |
Nonalcoholic fatty liver disease | 6 | - | 3.28 | 3 | - | 1.64 | |
Neoplasia | 4 | - | 2.19 | 3 | - | 1.64 | |
Psychiatric | 31 | - | 16.94 | 6 | - | 3.28 | |
Hypothyroidism | 9 | - | 4.92 | 2 | - | 1.09 | |
Inflammatory bowel disease | 1 | - | 0.55 | 0 | - | 0.00 | |
Others | 34 | - | 18.58 | 3 | - | 1.64 |
With Induction | Without Induction | ||||
---|---|---|---|---|---|
n (Patients) | % | n (Patients) | % | ||
Previous systemic treatments | 0 | 11 | 7.05 | 0 | 0.00 |
1 | 59 | 37.82 | 2 | 7.41 | |
2 | 59 | 37.82 | 14 | 51.85 | |
3 | 22 | 14.10 | 10 | 37.04 | |
4 | 5 | 3.21 | 1 | 3.70 | |
Previous biological treatments | 0 | 47 | 30.13 | 2 | 7.41 |
1 | 59 | 37.82 | 13 | 48.15 | |
2 | 29 | 18.59 | 8 | 29.63 | |
3 | 15 | 9.62 | 4 | 14.81 | |
4 | 6 | 3.85 | 0 | 0.00 |
Baseline | 1 Year | 2 Years | 3 Years | 4 Years | 5 Years | |
---|---|---|---|---|---|---|
PASI | 14.42 ± 10.47 (n = 156) | 2.03 ± 4.04 (n = 106) | 2.30 ± 5.34 (n = 81) | 1.31 ± 2.65 (n = 59) | 1.81 ± 4.35 (n = 39) | 0.68 ± 0.89 (n = 26) |
BSA | 12.79 ± 13.36 (n = 156) | 1.49 ± 3.31 (n = 100) | 1.81 ± 4.18 (n = 80) | 1.06 ± 3.00 (n = 58) | 1.75 ± 3.57 (n = 41) | 0.56 ± 0.71 (n = 26) |
PGA | 3.23 ± 1.17 (n = 156) | 0.70 ± 1.04 (n = 100) | 0.84 ± 1.09 (n = 78) | 0.57 ± 0.80 (n = 58) | 0.76 ± 1.02 (n = 41) | 0.52 ± 0.51 (n = 26) |
VAS pruritus | 7.64 ± 1.88 (n = 37) | 0.37 ± 0.84 (n = 35) | 0.43 ± 0.97 (n = 30) | 0.26 ± 0.53 (n = 26) | 0.35 ± 0.60 (n = 17) | 0.38 ± 0.50 (n = 13) |
Baseline | 1 Year | 2 Years | 3 Years | 4 Years | 5 Years | |
---|---|---|---|---|---|---|
PASI | 8.95 ± 3.96 (n = 27) | 0.04 ± 0.20 (n = 24) | 0.11 ± 0.32 (n = 19) | 0.0 ± 0.0 (n = 18) | 0.31 ± 0.63 (n = 13) | 0.71 ± 1.25 (n = 7) |
BSA | 14.37 ± 9.08 (n = 27) | 0.13 ± 0.61 (n = 24) | 0.32 ± 0.95 (n = 19) | 0.0 ± 0.0 (n = 18) | 0.85 ± 1.72 (n = 13) | 1.14 ± 2.04 (n = 7) |
PGA | 2.74 ± 0.71 (n = 27) | 0.04 ± 0.20 (n = 24) | 0.16 ± 0.50 (n = 19) | 0.0 ± 0.0 (n = 18) | 0.23 ± 0.44 (n = 13) | 0.29 ± 0.49 (n = 7) |
VAS pruritus | 6.73 ± 2.09 (n = 27) | 0.04 ± 0.20 (n = 24) | 0.05 ± 0.23 (n = 19) | 0.0 ± 0.0 (n = 18) | 0.23 ± 0.60 (n = 13) | 0.14 ± 0.38 (n = 7) |
N of Patients Who Discontinue | N of Patients at Risk2 | Survival Rate (95%CI) | |
---|---|---|---|
Baseline | 0 | - | - |
4 months | 14 | 176 | 92.04 (3.16–5.10) |
12 months | 13 | 153 | 84.22 (4.68–6.39) |
24 months | 9 | 116 | 77.69 (5.73–7.33) |
36 months | 2 | 88 | 75.92 (6.03–7.62) |
48 months | 3 | 61 | 72.19 (6.84–8.51) |
60 months | 0 | 41 | - |
Total N | 41 (22.40%) |
Initial Dose Time | With Induction | Without Induction | ||||
---|---|---|---|---|---|---|
n = 156 (85.25%) | n = 27 (14.75%) | |||||
N of Patients Who Discontinued Drug Use | N of Patients at Risk2 | Survival Rate (95%CI) | N of Patients Who Discontinued Drug Use | N of Patients at Risk2 | Survival Rate (95%CI) | |
Baseline | 0 | - | - | 0 | - | - |
4 months | 14 | 149 | 90.60 (3.72–5.95) | 0 | 27 | 100 |
12 months | 13 | 129 | 81.47 (5.43–7.32) | 0 | 24 | 100 |
24 months | 9 | 97 | 73.91 (6.59–8.29) | 0 | 19 | 100 |
36 months | 2 | 70 | 71.80 (6.93–8.61) | 0 | 18 | 100 |
48 months | 3 | 48 | 67.31 (7.91–9.64) | 0 | 13 | 100 |
60 months | 0 | 34 | - | 0 | 7 | 100 |
Total N | 41 | 0 | ||||
Log-rank (Mantel–Cox) test | ||||||
Chi square | 8.621 | |||||
p value | 0.0033 | |||||
Hazard Ratio (Mantel–Haenszel) | With induction vs. Without induction | With induction vs. Without induction | ||||
Ratio | 3.614 | 0.2767 | ||||
CI 95% | 1.533 to 8.522 | 0.1173 to 0.6523 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruiz-Villaverde, R.; Ezomo-Gervilla, P.J.; Molina-Espinosa, J.; Galán-Gutierrez, M.; Herrera-Acosta, E.; Suarez-Perez, J.A. Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study. J. Clin. Med. 2025, 14, 833. https://doi.org/10.3390/jcm14030833
Ruiz-Villaverde R, Ezomo-Gervilla PJ, Molina-Espinosa J, Galán-Gutierrez M, Herrera-Acosta E, Suarez-Perez JA. Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study. Journal of Clinical Medicine. 2025; 14(3):833. https://doi.org/10.3390/jcm14030833
Chicago/Turabian StyleRuiz-Villaverde, Ricardo, Pedro José Ezomo-Gervilla, Jose Molina-Espinosa, Manuel Galán-Gutierrez, Enrique Herrera-Acosta, and Jorge Alonso Suarez-Perez. 2025. "Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study" Journal of Clinical Medicine 14, no. 3: 833. https://doi.org/10.3390/jcm14030833
APA StyleRuiz-Villaverde, R., Ezomo-Gervilla, P. J., Molina-Espinosa, J., Galán-Gutierrez, M., Herrera-Acosta, E., & Suarez-Perez, J. A. (2025). Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study. Journal of Clinical Medicine, 14(3), 833. https://doi.org/10.3390/jcm14030833